These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34882663)

  • 21. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major Global Coronary Artery Calcium Guidelines.
    Golub IS; Termeie OG; Kristo S; Schroeder LP; Lakshmanan S; Shafter AM; Hussein L; Verghese D; Aldana-Bitar J; Manubolu VS; Budoff MJ
    JACC Cardiovasc Imaging; 2023 Jan; 16(1):98-117. PubMed ID: 36599573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines.
    Raygor V; Khera A
    Curr Cardiol Rep; 2020 Jul; 22(9):87. PubMed ID: 32647997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines.
    Pavlović J; Greenland P; Franco OH; Kavousi M; Ikram MK; Deckers JW; Ikram MA; Leening MJG
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007183. PubMed ID: 34546786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease.
    Mortensen MB; Nordestgaard BG
    Eur Heart J; 2020 Aug; 41(31):3005-3015. PubMed ID: 32227172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LDL as a therapeutic objective.
    Díaz Rodríguez Á; Mantilla Morató T
    Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():1-15. PubMed ID: 31813617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).
    ; Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
    Atherosclerosis; 2016 Oct; 253():281-344. PubMed ID: 27594540
    [No Abstract]   [Full Text] [Related]  

  • 34. Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention?
    Güntekin Ü; Gümrükçüoğlu HA; Yaman M; Öztürk F; Akyol A; Gümrükçüoğlu FN; Okudan YE; Tosun V; Kandemir YB
    Clin Ther; 2018 Dec; 40(12):2031-2040. PubMed ID: 30392816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
    Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
    Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
    Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
    Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D;
    Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445
    [No Abstract]   [Full Text] [Related]  

  • 39. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study.
    Gouni-Berthold I; Schaper F; Schatz U; Tabbert-Zitzler A; Fraass U; Sauer S; Ray KK
    Atheroscler Plus; 2022 Dec; 50():10-16. PubMed ID: 36643801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations.
    Zeitouni M; Sabouret P; Kerneis M; Silvain J; Collet JP; Bruckert E; Montalescot G
    Eur Heart J Cardiovasc Pharmacother; 2021 Jul; 7(4):324-333. PubMed ID: 32652000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.